Latest APG101 Stories
Up To 30 European Sites To Join 46 Active Sites In The US BETHESDA, Md., May 16, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®)-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax(®)-L for brain cancer has been initiated at King's College Hospital in the UK. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) This is one of the first...
ST. HELIER, Jersey, May 7, 2013 /PRNewswire/ -- Novocure announced today that the EF-14 pivotal clinical trial for patients with newly diagnosed glioblastoma (GBM) brain tumors has enrolled its first patient in Korea. This randomized, controlled trial is designed to enroll approximately 700 patients and will test the efficacy and safety of NovoTTF(TM) Therapy when added to the current best standard of care for newly diagnosed GBM. NovoTTF Therapy is delivered by a portable,...
Unprecedented Results Compared With Current Standard of Care BETHESDA, Md., April 18, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that Brad Silver, an All American swimming and water polo athlete who was diagnosed with Glioblastoma multiforme (GBM) brain cancer in late 2002, and was treated with DCVax-L in March of 2003, just celebrated the...
VANCOUVER, British Columbia and MENLO PARK, Calif., April 10, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C. during a clinical poster session entitled,...
HEIDELBERG, Germany, Feb. 7, 2013 /PRNewswire/ -- Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that its lead product, Apocept(TM) (APG101), has been granted orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of Myelodysplastic syndromes (MDS). MDS are clonal hematopoietic stem cell disorders characterized by ineffective...
VANCOUVER, British Columbia, Nov. 15, 2012 /PRNewswire/ -- Del Mar Pharmaceuticals (BC) Ltd. ("DelMar Pharma") today announced that the Company will present two scientific posters at the Society for Neuro-Oncology (SNO) 17(th) Annual Scientific Meeting, which is being held in Washington, DC November 15-18, 2012. On Friday November 16(th), DelMar will present a poster entitled, "VAL-083, Novel N7 Alkylating Agent, Surpasses Temozolomide Activity and Inhibits Cancer Stem Cells...
PORTSMOUTH, N.H., Nov. 14, 2012 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced today that preclinical and clinical data from studies evaluating NovoTTF(TM) Therapy will be presented at the 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) in Washington, D.C. The data presented sheds light on the subcellular mechanisms underlying the anti-cancer effect of NovoTTF Therapy and helps define which recurrent...
HEIDELBERG, Germany, Nov. 6, 2012 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, today announced that its lead product, Apocept(TM) (APG101), has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncology's "Top 10 Projects To Watch." This announcement is in conjunction with the "Therapeutic Area Partnerships" conference event taking...
